Cpd861 Targeting BCL2 to Alleviate Hepatic Fibrosis: Network Pharmacology, Mendelian Randomization, and Molecular Docking Mechanisms
This study made predictions regarding the efficacious components, as well as potential targets and pathways of Cpd861 in the therapy of HF. This will open up a new perspective for further investigation of the molecular mechanism of Cpd861 in the treatment of HF.
Authors
- Cheng Chi (ORCID: https://orcid.org/0000-0003-4908-0307)
- Chenghong Yin (ORCID: https://orcid.org/0000-0002-2503-3285)
- Jinming Li (ORCID: https://orcid.org/0000-0002-8595-1061)
- Xifeng Liang (ORCID: https://orcid.org/0000-0001-8986-3547)
- Shuhan Zhang (ORCID: https://orcid.org/0000-0002-9441-6386)
- Shuang Gao (ORCID: https://orcid.org/0000-0002-6360-3533)
- Jing Li
- Yaning Lyu
Institutions
- Capital Medical University (CN)
- Shandong First Medical University (CN)
- Beijing Obstetrics and Gynecology Hospital (CN)
- Jining Medical University (CN)
Publication Details
- Journal
- Current Pharmaceutical Design
- Published
- 2024-09-16
- DOI
- https://doi.org/10.2174/0113816128328422240820105654
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39